FI2945642T3 - Tekijä 1 proteiini käytettäväksi sairauksien hoitoon tai ehkäisemiseen - Google Patents

Tekijä 1 proteiini käytettäväksi sairauksien hoitoon tai ehkäisemiseen Download PDF

Info

Publication number
FI2945642T3
FI2945642T3 FIEP14700872.6T FI14700872T FI2945642T3 FI 2945642 T3 FI2945642 T3 FI 2945642T3 FI 14700872 T FI14700872 T FI 14700872T FI 2945642 T3 FI2945642 T3 FI 2945642T3
Authority
FI
Finland
Prior art keywords
protein
fragment
cardiomyopathy
seo
variant
Prior art date
Application number
FIEP14700872.6T
Other languages
English (en)
Finnish (fi)
Inventor
Kai Christoph Wollert
Mortimer Korf-Klingebiel
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Application granted granted Critical
Publication of FI2945642T3 publication Critical patent/FI2945642T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
FIEP14700872.6T 2013-01-17 2014-01-16 Tekijä 1 proteiini käytettäväksi sairauksien hoitoon tai ehkäisemiseen FI2945642T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151593 2013-01-17
PCT/EP2014/050788 WO2014111458A2 (en) 2013-01-17 2014-01-16 Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

Publications (1)

Publication Number Publication Date
FI2945642T3 true FI2945642T3 (fi) 2024-05-10

Family

ID=47559322

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP14700872.6T FI2945642T3 (fi) 2013-01-17 2014-01-16 Tekijä 1 proteiini käytettäväksi sairauksien hoitoon tai ehkäisemiseen

Country Status (16)

Country Link
US (1) US10369198B2 (cg-RX-API-DMAC7.html)
EP (2) EP3747457A3 (cg-RX-API-DMAC7.html)
JP (4) JP6809789B2 (cg-RX-API-DMAC7.html)
CN (6) CN111100197B (cg-RX-API-DMAC7.html)
CA (1) CA2898128A1 (cg-RX-API-DMAC7.html)
DK (1) DK2945642T3 (cg-RX-API-DMAC7.html)
ES (1) ES2986021T3 (cg-RX-API-DMAC7.html)
FI (1) FI2945642T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240623T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068364T2 (cg-RX-API-DMAC7.html)
LT (1) LT2945642T (cg-RX-API-DMAC7.html)
PL (1) PL2945642T3 (cg-RX-API-DMAC7.html)
PT (1) PT2945642T (cg-RX-API-DMAC7.html)
RS (1) RS65553B1 (cg-RX-API-DMAC7.html)
SI (1) SI2945642T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014111458A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100197B (zh) * 2013-01-17 2024-11-15 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10435757B1 (en) 2016-06-15 2019-10-08 University Of South Florida Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof
CN108802372B (zh) * 2018-06-19 2021-05-11 上海伦泽生物科技有限公司 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒
AU2021211874A1 (en) 2020-01-21 2022-08-25 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure
CN114149499B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用
CN114149498B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
CN114149500B (zh) * 2020-09-07 2023-12-01 复旦大学附属华山医院 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用
AU2021405790A1 (en) 2020-12-23 2023-07-06 Boehringer Ingelheim International Gmbh Viral capsid proteins with specificity to heart tissue cells
WO2023283649A1 (en) * 2021-07-08 2023-01-12 Tenaya Therapeutics, Inc. Optimized expression cassettes for gene therapy
US20250333459A1 (en) 2022-06-03 2025-10-30 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2024052564A1 (en) 2022-09-08 2024-03-14 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating cardiogenic shock
WO2025047991A1 (en) 2023-09-01 2025-03-06 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing a liver disorder
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2025120204A1 (en) 2023-12-06 2025-06-12 Boehringer Ingelheim International Gmbh Novel formulation comprising myeloid-derived growth factor
CN120738287A (zh) * 2025-07-03 2025-10-03 广州医科大学附属妇女儿童医疗中心 急性低灌注动物模型的构建方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
JP2002500502A (ja) 1996-06-11 2002-01-08 メルク エンド カンパニー インコーポレーテッド 合成ｃ型肝炎遺伝子
EP0932676A2 (en) * 1996-09-13 1999-08-04 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
JP2001506484A (ja) * 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
DE69827021T2 (de) * 1997-01-29 2005-02-24 Cornell Research Foundation, Inc. An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
CA2374180C (en) 1999-05-26 2012-09-11 Marita Hiipakka Methods and materials for generating sh3 domains with tailored binding properties
DE60038740T2 (de) * 1999-06-02 2009-07-02 Genentech, Inc., South San Francisco Stimulierung oder hemmung von angiogenese und herzvaskularisierung
CA2381985A1 (en) * 1999-08-16 2001-02-22 Universita'degli Studi Di Siena Vegf-d and angiogenic use thereof
CA2416538A1 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002081681A1 (fr) * 2001-03-30 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Nouvelle utilisation de la cytokine sf20
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
US7452968B2 (en) 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US8486438B2 (en) 2004-01-29 2013-07-16 Brown University Methods for progenitor cell recruitment and isolation
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US20080004232A1 (en) * 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2130547A1 (en) * 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
CN102741288B (zh) * 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
US8735342B2 (en) 2010-01-27 2014-05-27 Neumedicines, Inc. Method for treating brain cancer using a novel tumor suppressor gene and secreted factor
KR20120095063A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
CN111100197B (zh) * 2013-01-17 2024-11-15 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂

Also Published As

Publication number Publication date
JP7685737B2 (ja) 2025-05-30
EP2945642B1 (en) 2024-02-21
JP2016506911A (ja) 2016-03-07
EP2945642A2 (en) 2015-11-25
HK1215540A1 (en) 2016-09-02
CN110922468B (zh) 2024-09-24
DK2945642T3 (da) 2024-05-27
JP6809789B2 (ja) 2021-01-06
CN104968361A (zh) 2015-10-07
WO2014111458A3 (en) 2014-09-12
ES2986021T3 (es) 2024-11-08
EP3747457A3 (en) 2021-03-03
CN110922467A (zh) 2020-03-27
CN111100197A (zh) 2020-05-05
PT2945642T (pt) 2024-05-27
US10369198B2 (en) 2019-08-06
JP2023025005A (ja) 2023-02-21
WO2014111458A2 (en) 2014-07-24
CN111100197B (zh) 2024-11-15
US20150352186A1 (en) 2015-12-10
RS65553B1 (sr) 2024-06-28
CN110903378A (zh) 2020-03-24
EP3747457A2 (en) 2020-12-09
CN110894226A (zh) 2020-03-20
JP2025143268A (ja) 2025-10-01
SI2945642T1 (sl) 2024-07-31
CN110922468A (zh) 2020-03-27
LT2945642T (lt) 2024-06-25
HRP20240623T1 (hr) 2024-08-02
CN104968361B (zh) 2019-12-17
CA2898128A1 (en) 2014-07-24
JP2020203894A (ja) 2020-12-24
HUE068364T2 (hu) 2024-12-28
PL2945642T3 (pl) 2024-07-29

Similar Documents

Publication Publication Date Title
FI2945642T3 (fi) Tekijä 1 proteiini käytettäväksi sairauksien hoitoon tai ehkäisemiseen
Yang et al. Modified VEGF targets the ischemic myocardium and promotes functional recovery after myocardial infarction
JP2014521594A5 (cg-RX-API-DMAC7.html)
ES2398012T3 (es) Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
US20190343924A1 (en) Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
US20220235111A1 (en) Variant Single-Chain Insulin Analogues
CU20160013A7 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca
IL257764A (en) Methods of treating diseases
WO2016045493A1 (zh) 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物
US10736941B2 (en) Cell membrane-permeating peptide
EP2763673A1 (en) Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
JP5212492B2 (ja) 経鼻投与用医薬組成物
CN1198617C (zh) 治疗心脏舒张功能障碍的药物
JP5865347B2 (ja) ポリアミド化合物及びミトコンドリア遺伝子疾患治療用医薬組成物
WO2021037187A1 (zh) 一种多肽及其应用
CN101612384A (zh) 多肽小分子mlif在制备防治心肌缺血药物中的应用
CN110225922B (zh) 用于促进血管生成的剂及其方法和用途
JP2015524808A5 (cg-RX-API-DMAC7.html)
US8513301B2 (en) Kind of piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof
JP5103748B2 (ja) 医薬組成物
CN106822899B (zh) 一种通过抑制自噬促进心肌再生的药物
EP2996676A1 (en) Arginine-grafted bioreducible polymer systems and use in treatment of cardiac conditions
WO2019037393A1 (zh) 一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用
CN103705531A (zh) 灯盏花乙素在防治特异性血管内皮损伤中的应用
BR112019013531A2 (pt) Combinação, composição farmacêutica, medicamento, método para tratar leishmaniose, e, uso da composição.